To the Editor:Systemic lupus erythematosus(SLE)is an autoimmune disease involving multiple systems.In recent years,the therapeutic treat-to-target(T2T)strategy was recommended for SLE.^([1])The immunosuppressive drugs...To the Editor:Systemic lupus erythematosus(SLE)is an autoimmune disease involving multiple systems.In recent years,the therapeutic treat-to-target(T2T)strategy was recommended for SLE.^([1])The immunosuppressive drugs are the standard of care in SLE treatment.Tacrolimus was one of the calcineurin inhibitors which was recommended in the 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association recommendations for the management of lupus nephritis(LN)^([2]).展开更多
基金supported by grants from the Chinese National Key Technology R&D Program,Ministry of Science and Technology(Nos.2021YFC2501301-5,2017YFC0907601-3)Beijing Municipal Science&Technology Commission(No.Z201100005520022,23,25-27)CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2021-I2M-1-005).
文摘To the Editor:Systemic lupus erythematosus(SLE)is an autoimmune disease involving multiple systems.In recent years,the therapeutic treat-to-target(T2T)strategy was recommended for SLE.^([1])The immunosuppressive drugs are the standard of care in SLE treatment.Tacrolimus was one of the calcineurin inhibitors which was recommended in the 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association recommendations for the management of lupus nephritis(LN)^([2]).
